March 2020 at a glance: heart failure with preserved ejection fraction, left atrial myopathy, atrial fibrillation and cardiac amyloidosis

European Journal of Heart Failure, Volume 22, Issue 3, Page 389-390, March 2020.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: INTRODUCTION Source Type: research

Related Links:

659Objectives: Understanding the characteristics of patients with a final diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CA) may help optimally triage patients for Tc-99m pyrophosphate (PYP) scanning. The study was aimed to investigate the prevalence as well as the clinical features along with the electrocardiographic and echocardiographic characteristics of patients with ATTR-CA, who were referred for PYP scan after being hospitalized for decompensated heart failure. Methods: We included all the patients who were referred for PYP scan after heart failure-related hospitalization at our center between 06/2015 and 0...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Diagnostic and Prognostic Advances in Cardiac Radionuclide and Hybrid Imaging Source Type: research
AbstractAlthough the benefit of updated therapeutic regimens, including bortezomib, on the survival of immunoglobulin light chain (AL) amyloidosis patients with heart failure (HF) has been reported, predictors of mortality in the patients treated with the updated therapy remain unclear. We retrospectively enrolled AL amyloidosis patients who had severe HF at the time of diagnosis and received the updated therapy, including bortezomib (n = 19, 61 ± 6 years old, 68% male). Severe HF was defined as the presence of both NYHA functional class III or IV and BNP >  200 ...
Source: Heart and Vessels - Category: Cardiology Source Type: research
We present a 42 ‐year‐old male patient with familial transthyretin amyloidosis who suffered an embolic stroke that originated from a left atrial appendage thrombus in the absence of any documented atrial fibrillation. This case highlights atrial mechanical dysfunction in patients with cardiac amyloidosis and th e need to better stratify thrombotic risk in this population with integration of echocardiographic parameters and transesophageal echocardiography.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Case Report Source Type: research
Publication date: Available online 12 December 2019Source: Canadian Journal of CardiologyAuthor(s): Christopher C. Cheung, Thomas M. Roston, Jason G. Andrade, Matthew T. Bennett, Margot K. DavisAbstractCardiac amyloidosis occurs secondary to the deposition of insoluble protein fibrils in cardiac tissue leading to progressive myocardial dysfunction, clinical heart failure, and arrhythmia. In recent years, increasing awareness and improved screening have resulted in an increased prevalence of cardiac amyloidosis, with contemporary estimates reporting a prevalence of 18 to 55 cases per 100,000 person-years, and accounting for...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Researchers here argue that fibrosis of cardiac tissue is an important contribution to the development of atrial fibrillation in older patients. Fibrosis is a feature of many age-related conditions, a dysfunction in tissue maintenance processes that involves the generation of scar-like deposits of collagen by overactive fibroblasts. This scarring disrupts normal tissue structure and function in many organs, including the heart, and there is no good approved therapy to treat the progression of fibrosis: even slowing it is haphazard and unreliable. This may soon change. Fibrosis appears to be caused to a large degree ...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
In conclusion, T2D impairs vascular function by dysregulated autophagy. Therefore, autophagy could be a potential target for overcoming diabetic microvascular complications. To What Degree Does Loss of Skeletal Muscle with Age Contribute to Immunosenescence? Sarcopenia, the progressive loss of muscle mass and strength, is characteristic of aging. A perhaps surprisingly large fraction of the losses can be averted by strength training, but there are nonetheless inexorable process...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In this study, we sought to assess the prevalence of AF in patients with clinically undetected isolated cardiac amyloidosis (ICA) detected at autopsy and identify electrocardiographic (EKG) markers of such amyloid deposits. A total of 1083 patients were included in the study and 3.1% of patients were found to have asymptomatic ICA. Patients with ICA were older and had a higher odds of AF independent of age and CHA2DS2VASc score. Amongst patients with AF, those with ICA were more likely to have persistent forms of AF and had a lower sinus rhythm P-wave amplitude. Further studies are required to further define this entity, i...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
In conclusion, we provide novel insights regarding the molecular basis of ATTRm and ATTRwt based on large-scale cohort, expanding our understanding of the phenotypic spectrum associated withTTR gene variation.
Source: Human Genetics - Category: Genetics & Stem Cells Source Type: research
With limited options for rate control of atrial fibrillation in the setting of low-output heart failure (HF), digoxin may appear to be a reasonable option for patients with cardiac amyloidosis (CA). However, current guidelines, based on historical case reports and an in vitro study, state that digoxin should generally be avoided in CA due to increased sensitivity for digoxin toxicity. A recent study of 107 patients with AL amyloidosis given digoxin showed relative safety with cautious use, with 11% of patients developing significant arrhythmias.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: 059 Source Type: research
More News: Amyloidosis | Atrial Fibrillation | Cardiology | Heart | Heart Failure